Mary Kay Ladone

September 7, 2026

Analyst Reiterates Rating on Kestra Medical Technologies with $32 Target. BTIG has reiterated its positive view on Kestra Medical Technologies, keeping a $32 price target on the stock. The reaffirmation comes as broader medical device peers report mixed quarterly results: Phreesia fell short of Q2 earnings and revenue estimates, while Medtronic beat on both lines. These peer results provide context for the medical device sector backdrop against which Kestra is being evaluated.

September 29, 2026

Medical device growth debate touches Inogen sector. A recent Yahoo article examined whether ResMed or Stryker offers a better path to capture medical device growth. Inogen operates in the same medical device market, so the analysis is relevant to how the sector is being evaluated. The discussion may influence how market participants view companies that provide portable oxygen solutions.

October 8, 2026

Novanta Shares Rise Amid Positive Analyst Mentions. Recent reports highlight Novanta as a stock gaining attention from Wall Street, with one article noting its shares skyrocketed alongside other names. The company is currently trading near its 52-week low, despite analysts maintaining a higher average target price. This divergence suggests the market is currently pricing in significant caution regarding the stock's high valuation.